Linsitinib_867160-71-2_DataSheet_MedChemExpress

References: [1]. Arnold, Lee D.; Cesario, Cara; Coate, Heather; Crew, Andrew Philip; Preparation of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors. PCT Int. Appl. (2005), 653 pp. CODEN: PIXXD2 WO 2005097800 无 [2]. [ ] Mulvihill MJ, , Cooke A, , Rosenfeld-Franklin M, , Buck E, , Foreman K, , Landfair D, , O'Connor M, , Pirritt C, Sun Y, Yao Y, Arnold Lห้องสมุดไป่ตู้, Gibson NW, Ji QS.Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.Future Med Chem. 2009 Sep;1(6):1153-71. [3]. McKinley ET, Bugaj JE, Zhao P, Guleryuz S, Mantis C, Gokhale PC, Wild R, Manning HC.18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.Clin Cancer Res. 2011 May 15;17(10):3332-40. Epub 2011 Jan 21. [4]. Zhao H, Desai V, Wang J, Epstein DM, Miglarese M, Buck...
Product Data Sheet
Product Name: CAS No.: Cat. No.: MWt: Formula: Purity : Linsitinib 867160-71-2 HY-10191 421.49 C26H23N5O >98%
Solubility:
DMSO ≥81mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL Pathways:Protein Tyrosine Kinase/RTK; Target:IGF-1R Pathways:Protein Tyrosine Kinase/RTK; Target:IR
Mechanisms:
g y Biological Activity: Linsitinib is highly potent, orally efficacious and highly selective, dual ATP-competitive tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) (IC50: 35 nM) and insulin receptor (IR) (IC50: 75 nM).
Caution: Not fully tested. For research purposes only Medchemexpress LLC

m o c . s s e r p x e m e h c d e m . w w w : b e AW Sm U o ,c 0 . 4s 5s 8e 0r p Jx Ne ,m n e oh t c e cd ne i m r P @ o ,f y n a i Wl : ni a om s E n i k l i W 8 1